Issued on behalf of Oncolytics Biotech Inc.
Oncolytics Biotech Inc. (NASDAQ:ONCY) (TSX:ONC) is making headlines with promising results from its BRACELET-1 trial in breast cancer, showing a 12.1-month progression-free survival (PFS) and over half the patients still alive at the study’s end. With a STRONG BUY rating from analysts and a $5.20 price target (currently $0.93, as of Sept 19, 2024), this is a unique opportunity to invest in a rising star in cancer therapy. Get ahead of the crowd before the news spreads!
Cancer—a word that strikes fear into the hearts of many. But a revolution in how this formidable foe is fought is on the horizon.
Recent trends show that Generation X and millennials are being diagnosed with cancer at rates higher than ever before.[1] This isn’t just a fluke—it’s a trend reshaping the understanding of health in modern society.
The reasons are complex. Lifestyle changes[2], environmental factors[3], and genetic predispositions[4] all play a role. But the impact is clear. More people are facing the challenge of cancer, and the burden on families and healthcare systems is growing.
The economic cost? Staggering. The global economic impact is projected to exceed $25 trillion over the next three decades.[5] This figure highlights the urgent need for innovation in cancer treatment.
Traditional treatments like chemotherapy and radiation have their limits. While they’ve saved countless lives, there’s a growing consensus that new approaches are needed—treatments that are not just effective but also kinder and more targeted.
This is where the promise of innovation comes in. Analysts project significant growth in the oncology market, driven by breakthroughs that are changing the game.
The global cancer therapeutics market is projected by Allied Market Research to grow from $98.9 billion in 2018 to $180.2 billion by 2026, at a 7.7% CAGR.[6]
The global breast cancer drugs market is anticipated by Data Bridge Market Research to grow from $30.2 billion in 2022 to $55.9 billion by 2030, reflecting a CAGR of 8.2%.[7]
According to TMR Research, the pancreatic cancer treatment market is expected to grow at a CAGR of 12.4%, reaching approximately $10.2 billion by 2034.[8]
Big Pharma is taking note of this crisis. Major players like AstraZeneca, Roche, and Pfizer are investing billions in acquiring biotech firms that pioneer groundbreaking cancer treatments. [9],[10],[11],[12],[13],[14]
Imagine treatments that don’t just attack cancer cells but empower the body’s own defenses to fight back.
It’s not just a dream. It’s happening now. A new wave of therapies is on the horizon, poised to transform the way cancer treatment is approached.
But what’s the next big thing in this evolving landscape? What groundbreaking therapy is making headlines, promising to change the way cancer is fought forever?
Enter pelareorep—a groundbreaking therapy that could one day redefine cancer treatment as we know it.
This innovative immunotherapy is making waves in the medical community by leveraging the body’s immune system to target and destroy cancer cells.
Recent trials have shown promising results, with significant improvements in survival rates for patients with some of the most challenging cancers.[15]
The driving force behind this revolutionary treatment is Oncolytics Biotech Inc. (NASDAQ:ONCY) (TSX:ONC), a pioneering company at the forefront of immunotherapy innovation.
Oncolytics Biotech Inc. (NASDAQ:ONCY) (TSX:ONC)
With a commitment to improving the quality of life for cancer patients, Oncolytics is harnessing the potential of pelareorep to unlock the body’s antitumor capabilities.
In clinical studies, pelareorep has demonstrated remarkable success, particularly in metastatic breast cancer and pancreatic cancer. Breast cancer patients treated with pelareorep and standard chemotherapy have shown nearly double the survival rates compared to traditional chemotherapy alone. This breakthrough has not gone unnoticed.
Backed by collaborations with industry giants like Pfizer, Roche, and Merck, Oncolytics Biotech is advancing pelareorep to late-stage clinical trials. With both breast cancer and pancreatic cancer having FDA Fast Track Designation, the path to regulatory approval is being accelerated, potentially offering hope to millions.
But how does this innovative treatment work? And what does it mean for the future of cancer care? Stay tuned as we delve deeper into the science behind pelareorep and the potential it holds for transforming cancer treatment.
The Top 7 Reasons Oncolytics Biotech Inc. (NASDAQ:ONCY) (TSX:ONC) is a Name to Watch in Biotech
1 Regulatory Triumphs: Oncolytics Biotech is making significant strides with TWO FDA Fast Track Designations for pelareorep[16],[17], expediting the review process on the path toward potential regulatory approval. This designation is a game-changer, opening doors for faster review and greater collaboration with regulatory bodies, as the company moves closer towards a registration-enabling trial in HR+/HER2- metastatic breast cancer[18] expected in 2025.
2 Strategic Alliances: Collaborating with industry leaders like Pfizer, Roche, and Merck,[19] Oncolytics is leveraging these partnerships to enhance clinical development and expand pelareorep’s potential across multiple cancer types.
3 Clinical Breakthroughs: In recent trials, pelareorep has shown exceptional promise, particularly in HR+/HER2- metastatic breast cancer[20], where in combination with chemotherapy it achieved the median progression-free survival (PFS) of 12.1 months, nearly double the 6.4 months seen in patients receiving chemo alone. And because more than half of the patients were still alive at the study’s conclusion, the median overall survival (OS) couldn’t be determined, a GREAT sign, putting estimates around 32 months compared to 18.2 months for chemo alone.
4 Market Expansion: Positioned in a booming oncology market, Oncolytics is set to capture a significant share as analysts project substantial growth driven by innovative cancer therapies. The company’s focus on cutting-edge treatment places it at the forefront of this market expansion.
5 Expert Leadership: Led by a team of seasoned professionals, Oncolytics Biotech boasts decades of experience in drug development and commercialization. Their expertise is guiding the company through pivotal clinical milestones and strategic growth.
6 Robust Financial Health: With a strong cash position of $24.9 million, Oncolytics has the financial runway to support ongoing research and achieve key milestones into 2025.[21] This stability enables continued innovation and development.
7 Commitment to Innovation: Oncolytics remains steadfast in its mission to advance cancer research. By pushing the boundaries of immunotherapy, the company is transforming how cancer is treated, with pelareorep leading the charge.
Believe in the Experts: A ‘Strong Buy’
Wall Street is buzzing with excitement over Oncolytics Biotech Inc. (NASDAQ:ONCY) (TSX:ONC) with experts on NASDAQ.com, shouting a resounding STRONG BUY!
Analysts have set their sights high, with an average price target of $5.20 and a top estimate of $6.60. With the stock currently hovering around $0.93 (as of Sept 19, 2024), that’s a potential rocket ship ride to more than five times its current value—a jaw-dropping +459% increase!
So, what do these savvy analysts know that others might be missing? While we can’t spill their secrets, it’s clear why Oncolytics Biotech is one of the hottest opportunities we’ve come across in years.
You’ve already seen why Oncolytics Biotech Inc. (NASDAQ:ONCY) (TSX:ONC) is on its way to superstardom, with game-changing advancements in the pipeline. Now is the perfect time for investors to jump on board and take action!
Pelareorep: Mechanism and Potential
Oncolytics Biotech Inc. (NASDAQ:ONCY) (TSX:ONC) is a trailblazer in cancer treatment, harnessing the power of the body’s immune system with pelareorep to target and eliminate cancer cells. This immunotherapeutic agent works by enhancing the effectiveness of chemotherapy and immunotherapy, transforming the tumor microenvironment to be more hostile to cancer.
How does it do this? Pelareorep transforms the tumor microenvironment by generating and recruiting immune cells to recognize and attack cancer. It enhances immune response by introducing double-stranded RNA into cancer cells, leading to inflammation and upregulation of PD-L1, which helps T-cells infiltrate and destroy the tumor.
This innovative approach allows pelareorep to work in harmony with chemotherapy, immune checkpoint inhibitors, and other therapies, boosting their effectiveness and offering hope for longer-lasting remissions.
Research and development efforts are in full swing, with key clinical trials like BRACELET-1 for breast cancer and GOBLET for pancreatic and anal cancer leading the charge. These studies have shown impressive results, including significant improvements in progression-free survival and overall survival rates.
Pelareorep’s potential is expansive, offering hope across multiple cancer types by converting “cold” tumors into “hot” ones, making them more susceptible to immune attack. It’s not just another cancer treatment—it’s a revolutionary approach to unleashing the full power of the immune system.
Transforming Breast Cancer Treatment
Breast cancer remains a formidable challenge, with over 310,000 new cases estimated to be diagnosed in the U.S. in 2024.[22] But with Oncolytics Biotech Inc.’s (NASDAQ:ONCY) (TSX:ONC) pelareorep, there’s new hope. It’s already showing big improvements for patients with HR+/HER2- metastatic breast cancer, especially those who have exhausted other options.
With annual expenses reaching a total of $29.8 billion[23]. HR+/HER2- metastatic breast cancer patients often face limited options once hormonal therapy fails, leaving a significant unmet need in treatment.[24]
Recently Oncolytics reported favorable positive clinical results from its randomized Phase 2 study, BRACELET-1,[25] reinforcing their path towards funding a registration-enabling study. [26]
A registration-enabling study is a pivotal clinical trial that is designed to provide the necessary data for a New Drug Application (NDA) submission to the FDA for approval.
Within the latest BRACELET-1 results, pelareorep (when combined with chemotherapy) helped patients go 12.1 months before their cancer got worse (median PFS)—almost double the time for patients on chemotherapy alone.[27]
Even better, most patients were still alive when the study ended, showing just how powerful this treatment could be. The median overall survival (OS) could not be determined, as more than half of the patients were still alive at the study’s conclusion, but estimates put OS at approximately 32 months compared to 18.2 months for chemotherapy alone.
This data builds on the strong findings from the earlier IND-213 study, which also demonstrated a significant survival benefit when combining pelareorep with chemotherapy. Given this consistent success, Oncolytics Biotech is seemingly advancing pelareorep toward a registration-enabling trial[28].
FDA Process and Market Potential
Back in 2017, the FDA already awarded pelareorep with Fast Track Designation for the treatment of metastatic breast cancer [29], speeding up the regulatory review process and its path to potential approval.
How significant would a potential approval be?
The breast cancer drug market is poised for rapid growth, with projections from BioSpace showing it will grow from $32.93 billion in 2023 to $78.61 billion by 2033[30]. Additionally, DelveInsight predicts a 9.3% CAGR for the HR+/HER2- metastatic breast cancer market alone[31], underscoring the significant commercial opportunity for new treatments
With promising results and regulatory momentum, pelareorep is poised to make a significant impact in the fight against breast cancer, offering new hope to patients worldwide.
Tackling Pancreatic Cancer
Pancreatic cancer. It’s known as the “silent killer,” and for a good reason. Each year, about 66,440 people in the U.S. are expected to be diagnosed[32], and it’s one of the deadliest cancers, with a five-year survival rate of just 13%.[33]
The symptoms are subtle, often going unnoticed until it’s too late, and the incidence rate among young women has skyrocketed by 208% over the past 30 years.[34]
Enter pelareorep, a game-changing therapy with the potential to turn the tide. In clinical trials, pelareorep has been making waves, especially when combined with treatments like chemotherapy and immune checkpoint inhibitors.
Recent data from the GOBLET study revealed a remarkable 62% objective response rate,[35] more than doubling the results of historical control trials.[36]
This promising progress hasn’t gone unnoticed. The Pancreatic Cancer Action Network (PanCAN) awarded Oncolytics Biotech a $5 million Therapeutic Accelerator Award to support the continued development of pelareorep.[37]
The FDA has also taken notice, granting pelareorep Fast Track Designation, accelerating its journey toward potential approval.[38]
Backed by robust collaborations and cutting-edge science, pelareorep is not just making headlines—it’s potentially poised to set new standards in pancreatic cancer treatment. With each success, pelareorep is proving that the future of cancer treatment is nearly here, and it could be brighter than ever.
Advancing Solutions for Anal Cancer
The number of new anal cancer cases has been rising for many years, with a rise in incidence of 2.7% annually for the past decade in the USA[39]. The number of people who die from anal cancer each year has also been rising[40].
Contributing factors include HPV infection, lowered immunity, and smoking[41]. There are treatment options for anal cancer, but they usually do not come cheaply.
In a 2018 study published in the Journal of Managed Care + Specialty Pharmacy, it was determined the average cost of the first 2 years of anal cancer treatment to be $127,531.[42]
The American Cancer Society estimates about 10,540 new cases of anal cancer in 2024 (3,360 in men, and 7,180 in women), with about 2,190 deaths (1,000 in men, and 1,190 in women). [43]
In response to this growing concern, Oncolytics Biotech Inc. (NASDAQ:ONCY) (TSX:ONC) is positioning pelareorep towards the forefront of innovative treatment strategies. This cutting-edge therapy is being integrated into combination therapies, and currently being tested in clinical trials alongside immune checkpoint inhibitors and chemotherapy.[44]
Recent trials have shown promising results, with pelareorep delivering positive interim data from the unresectable squamous cell carcinoma of the anal canal (SCCA) cohort of the Phase 2 GOBLET study, including a complete response in an indication where checkpoint inhibitor therapy alone has had limited success historically.[45] These results demonstrated an almost a 3X improvement compared to data from like studies evaluating checkpoint inhibitors in patients with more than one prior line of therapy.[46],[47],[48]
With the support of leading pharmaceutical companies and academic institutions, Oncolytics Biotech is advancing pelareorep through a strategic pathway toward potential regulatory approval. The future implications are profound, offering a beacon of hope for more effective cancer care.
Financial Position and Market Overview
Oncolytics Biotech Inc. (NASDAQ:ONCY) (TSX:ONC) stands on solid financial ground, boasting a cash position of $24.9 million, which provides a financial runway through key milestones well into 2025.[49]
This robust financial health is crucial for advancing pelareorep through pivotal clinical trials, including the registration-enabling studies for breast and pancreatic cancers.
The company’s share structure is designed to support its growth strategy, ensuring stability as Oncolytics continues to push the boundaries of immunotherapy.
AS MENTIONED ABOVE: Analysts consistently recognize Oncolytics’ strong market position and potential for substantial growth, with 6 analysts offering a consensus STRONG BUY rating.[50]
Recent strategic collaborations, such as the partnership with the Global Coalition for Adaptive Research (GCAR)[51] and funding from PanCAN,[52] underscore the company’s capability to secure critical resources and partnerships. These alliances not only bolster Oncolytics’ financial standing but also accelerate its path toward revolutionizing cancer treatment with pelareorep.
With a strategic financial framework and an innovative pipeline, Oncolytics Biotech Inc. (NASDAQ:ONCY) (TSX:ONC) is poised for growth, paving the way for groundbreaking advancements in oncology.
ONCY Among Its Peers
Now let’s look at how Oncolytics Biotech Inc. (NASDAQ:ONCY) (TSX:ONC) stacks up to its peers as a potential takeout target in the future by pharma giants looking for an oncology winner:
It’s clear that in the world of cancer treatment, Oncolytics Biotech Inc. (NASDAQ:ONCY) (TSX:ONC) stands out in this busy field.
MEET THE EXPERTS AT ONCOLYTICS BIOTECH
Developing a revolutionary treatment like pelareorep requires a powerhouse team, and Oncolytics Biotech Inc. (NASDAQ:ONCY) (TSX:ONC) has just the right lineup to deliver. With experience from industry giants like Amgen, Bristol-Myers Squibb, and academic institutions such as Harvard Medical School, Oncolytics’ team is second to none.
Getting a new medical treatment like pelareorep ready for patients involves many steps and a skilled team. The experts at Oncolytics Biotech Inc. (NASDAQ:ONCY) (TSX:ONC) are just the right people for the job. They have worked at leading companies and universities, such as Amgen, Bristol-Myers Squibb, and Harvard Medical School.
Currently leading the charge is Wayne Pisano, Interim CEO and Chair of the Board, stepping in for Dr. Matt Coffey during his medical leave. Wayne Pisano is an industry veteran with over 30 years of experience in pharmaceuticals and 12 years in biotech.
Formerly the President and CEO of Sanofi Pasteur, he played a pivotal role in making it a leader in the global influenza vaccine market.[53] Pisano’s interim leadership at Oncolytics ensures the company remains on track to achieve its strategic priorities and advance pelareorep through critical clinical milestones.
Let’s meet some of them:
Matt Coffey, PhD, MBA – Co-Founder, Director, President & CEO
A leading expert in cancer virotherapy, Dr. Coffey has dedicated his career to studying how viruses can be harnessed to combat cancer. His groundbreaking research has been published in numerous prestigious scientific journals. Currently on medical leave, his vision continues to guide Oncolytics’ mission and strategy.
Patricia S. Andrews – Director
An accomplished biopharmaceutical executive, Pat Andrews brings extensive experience in navigating registrational trials and completing transformative business deals. Her strategic insights are instrumental as Oncolytics advances pelareorep toward pivotal studies.
Thomas Heineman, MD, PhD – Head of Clinical Development and Operations
With over 25 years in drug development, Dr. Heineman has led numerous oncology projects, focusing on advancing treatments for cancers such as breast and pancreatic cancer.
Deborah M. Brown, B.Sc., MBA – Director
Known for her strategic leadership at EMD Serono and Accelera Canada, Deborah Brown is instrumental in guiding new medical businesses to success.
Bernd R. Seizinger, MD, PhD – Director
An expert in cancer drug discovery, Dr. Seizinger has served in top roles at Harvard Medical School and Princeton University, contributing to groundbreaking advancements in oncology.
Oncolytics Biotech Inc.’s (NASDAQ:ONCY) (TSX:ONC) team is stacked with top-tier talent, from the Board of Directors to the Scientific Advisory Board. Each member brings invaluable expertise from leading organizations, making Oncolytics a formidable force in the biotech industry.
Guided by these exceptional minds, Oncolytics Biotech Inc. (NASDAQ:ONCY) (TSX:ONC) is paving the way for innovative cancer therapies that could change the lives of patients worldwide.
In short, it is guided by some of the best minds in the business.
RECAP: 7 Things to Remember About Oncolytics Biotech Inc. (NASDAQ:ONCY) (TSX:ONC)
1. Regulatory Triumphs
2. Strategic Alliances
3. Clinical Breakthroughs
4. Market Expansion
5. Expert Leadership
6. Robust Financial Health
7. Commitment to Innovation
Join the Cancer Treatment Revolution!
The world of cancer treatment is on the brink of a transformation, and Oncolytics Biotech Inc. (NASDAQ:ONCY) (TSX:ONC) is leading the charge. With pelareorep paving the way for groundbreaking advancements, the potential to change the lives of millions of patients has never been more tangible.
Oncolytics Biotech stands at the forefront of this revolution, backed by a team of industry leaders, strategic collaborations, and a robust financial position. The journey to redefine cancer care is underway, and the opportunity to be part of this exciting evolution is now.
Investors and collaborators are invited to join Oncolytics Biotech in this mission to push the boundaries of what’s possible in cancer treatment. Whether through strategic collaborations or financial investment, there’s a place for you in this groundbreaking endeavor.
The future of oncology is here, and it holds the promise of more effective, personalized treatments that could change the face of medicine.
So, take some time to do your own research, and don’t forget to sign up for email alerts. That way, you’ll stay updated on all the exciting news and milestones from ONCY. We’re here to keep you informed!
USA News Group
Editorial Staff
DISCLAIMER: Nothing in this publication should be considered as personalized financial advice. We are not licensed under securities laws to address your particular financial situation. No communication by our employees to you should be deemed as personalized financial advice. Please consult a licensed financial advisor before making any investment decision. This is a paid advertisement and is neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this report or email is not provided to any individual with a view toward their individual circumstances. USA News Group is a wholly-owned subsidiary of Market IQ Media Group, Inc. (“MIQ”). MIQ has been paid a fee for Oncolytics Biotech Inc. advertising and digital media from the company directly. There may be 3rd parties who may have shares of Oncolytics Biotech Inc., and may liquidate their shares which could have a negative effect on the price of the stock. This compensation constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled company. Because of this conflict, individuals are strongly encouraged to not use this publication as the basis for any investment decision. The owner/operator of MIQ own shares of Oncolytics Biotech Inc. which were purchased in the open market, and reserve the right to buy and sell, and will buy and sell shares of Oncolytics Biotech Inc. at any time without any further notice. We also expect further compensation as an ongoing digital media effort to increase visibility for the company, no further notice will be given, but let this disclaimer serve as notice that all material disseminated by MIQ has been approved by the above mentioned company; this is a paid advertisement, we currently own shares of Oncolytics Biotech Inc. and will buy and sell shares of the company in the open market, or through private placements, and/or other investment vehicles.
While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between the any predictions and actual results. Always consult a licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.
SOURCES CITED:
[1] https://www.today.com/health/disease/cancer-rising-millennials-study-rcna164610
[2] https://www.cityofhope.org/whats-behind-rising-colorectal-cancer-rates-in-young-adults
[3] https://abcnews.go.com/Health/cancer-deaths-declining-troubling-increase-colon-breast-cancer/story?id=106427957
[4] https://edition.cnn.com/2024/07/31/health/millennials-gen-x-cancer-risk-study/index.html
[5] https://www.healio.com/news/hematology-oncology/20230223/global-economic-cost-of-cancer-estimated-to-exceed-25-trillion-over-30-years
[6] https://www.einnews.com/pr_news/728043865/cancer-therapeutics-market-exploring-global-investment-and-r-d-trends-cagr-7-7
[7] https://www.openpr.com/news/3596177/breast-cancer-drugs-market-size-share-trends-key-drivers
[8] https://www.openpr.com/news/3585977/at-a-cagr-of-12-4-pancreatic-cancer-treatment-market
[9] https://www.reuters.com/breakingviews/super-chemo-will-be-big-pharmas-next-tussle-2022-05-16/
[10] https://www.forbes.com/sites/greatspeculations/2019/07/10/was-the-47-billion-acquisition-of-genentech-in-2009-a-good-deal-for-roche/?sh=5c78818aa1aa
[11] https://www.fiercebiotech.com/biotech/eat-me-pfizer-swallows-cd47-biotech-trillium-2-3b-takeover
[12] https://www.wsj.com/business/ftc-settles-with-amgen-over-27-8-billion-deal-for-horizon-therapeutics-b96a2d69
[13] https://ir.horizontherapeutics.com/news-releases/news-release-details/horizon-therapeutics-plc-announces-fda-approval-update
[14] https://www.fiercebiotech.com/biotech/sanofi-inks-2-5b-synthorx-takeover-to-gain-il-2-cancer-drug
[15] https://oncolyticsbiotech.com/press_releases/oncolytics-biotech-reports-favorable-results-for-bracelet-1-breast-cancer-study-reinforcing-path-to-funding-of-a-registration-enabling-study/
[16] https://oncolyticsbiotech.com/press_releases/oncolytics-biotech-receives-fda-fast-track-designation-for-the-treatment-of-advanced-metastatic-pancreatic-cancer/
[17] https://oncolyticsbiotech.com/press_releases/oncolytics-biotech-inc-announces-fda-fast-track-designation-for-reolysin-in-metastatic-breast-cancer/
[18] https://oncolyticsbiotech.com/press_releases/oncolytics-biotech-announces-productive-fda-type-c-meeting-on-its-metastatic-breast-cancer-program/
[19] https://oncolyticsbiotech.com/pipeline/
[20] https://oncolyticsbiotech.com/press_releases/oncolytics-biotech-advances-toward-registration-enabling-trial-for-pelareorep-in-breast-cancer-with-submission-of-type-c-meeting-request-to-fda-2/
[21] https://oncolyticsbiotech.com/press_releases/oncolytics-biotech-reports-second-quarter-2024-financial-results-and-operational-highlights/
[22] https://www.cancer.org/cancer/types/breast-cancer/about/how-common-is-breast-cancer.html
[23] https://www.cdc.gov/nccdphp/priorities/breast-cancer.html#:~:text=%2429.8%20billion%3A2-,Breast%20cancer%20has%20the%20highest%20treatment%20cost%20of%20any%20cancer,%243.5%20billion%20for%20prescription%20drugs.
[24] https://www.mdanderson.org/newsroom/sabcs-studies-suggest-novel-targeted-therapies-may-benefit-patients-metastatic-hr-plus-her2-breast-cancer.h00-159624168.html
[25] https://oncolyticsbiotech.com/press_releases/oncolytics-biotech-reports-favorable-results-for-bracelet-1-breast-cancer-study-reinforcing-path-to-funding-of-a-registration-enabling-study/
[26] https://oncolyticsbiotech.com/press_releases/oncolytics-biotech-announces-productive-fda-type-c-meeting-on-its-metastatic-breast-cancer-program/
[27] https://oncolyticsbiotech.com/press_releases/oncolytics-biotech-reports-favorable-results-for-bracelet-1-breast-cancer-study-reinforcing-path-to-funding-of-a-registration-enabling-study/
[28] https://www.onclive.com/view/fda-receives-type-c-meeting-request-for-pelareorep-in-hr-her2-metastatic-breast-cancer
[29] https://oncolyticsbiotech.com/press_releases/oncolytics-biotech-inc-announces-fda-fast-track-designation-for-reolysin-in-metastatic-breast-cancer/
[30] https://www.biospace.com/breast-cancer-drugs-market-size-to-surpass-usd-78-61-bn-by-2033
[31] https://www.prnewswire.com/news-releases/metastatic-hrher2-breast-cancer-market-is-expected-to-showcase-a-significant-growth-at-a-cagr-of-9-3-by-2032–predicts-delveinsight-302004113.html
[32] https://www.cancer.org/cancer/types/pancreatic-cancer/about/key-statistics.html
[33] https://pancan.org/news/pancreatic-cancer-five-year-survival-rate-increases-to-13/
[34] https://www.dailymail.co.uk/health/article-13033795/Huge-spike-cancer-sparks-alarm-experts-baffled.html
[35] https://oncolyticsbiotech.com/press_releases/oncolytics-presents-positive-updated-pancreatic-cancer-data-from-goblet-phase-1-2-study-at-esmo/
[36] https://www.nejm.org/doi/full/10.1056/NEJMoa1304369
[37] https://pancan.org/news/pancans-5-million-therapeutic-accelerator-award-goes-to-oncolytics-biotech-inc/
[38] https://oncolyticsbiotech.com/press_releases/oncolytics-biotech-receives-fda-fast-track-designation-for-the-treatment-of-advanced-metastatic-pancreatic-cancer/
[39] https://pubmed.ncbi.nlm.nih.gov/31742639/
[40] https://seer.cancer.gov/statfacts/html/anus.html
[41] https://www.cancer.org/cancer/types/anal-cancer/causes-risks-prevention/what-causes.html
[42] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10397580/
[43] https://www.cancer.org/cancer/types/anal-cancer/about/what-is-key-statistics.html
[44] https://oncolyticsbiotech.com/press_releases/oncolytics-biotech-initiates-enrollment-expansion-of-goblet-anal-cancer-cohort/
[45] https://oncolyticsbiotech.com/press_releases/oncolytics-announces-the-anal-cancer-cohort-of-the-goblet-phase-1-2-study-of-pelareorep-and-atezolizumab-has-met-the-success-criteria-for-efficacy/
[46] https://pubmed.ncbi.nlm.nih.gov/28453692/
[47] https://pubmed.ncbi.nlm.nih.gov/28223062/
[48] https://pubmed.ncbi.nlm.nih.gov/35816951/
[49] https://pubmed.ncbi.nlm.nih.gov/35114169/
[49] https://pubmed.ncbi.nlm.nih.gov/34815354/
[49] https://pubmed.ncbi.nlm.nih.gov/32334548/
[50] https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2022.935383/fulless_releases/oncolytics-biotech-announces-preliminary-collaboration-with-gcar-for-inclusion-of-pelareorep-in-anticipated-pancreatic-cancer-trial/”https://oncolyticsbiotech.com/press_releases/oncolytics-biotech-announces-preliminary-collaboration-with-gcar-for-inclusion-of-pelareorep-in-anticipated-pancreatic-cancer-trial/
[52] https://pancan.org/press-releases/the-pancreatic-cancer-action-network-selects-oncolytics-biotech-inc-to-receive-5-million-therapeutic-accelerator-award-to-develop-leading-edge-treatments/
[53] https://oncolyticsbiotech.com/press_releases/oncolytics-biotech-announces-president-and-chief-executive-officer-dr-matt-coffey-to-take-medical-leave-of-absence/